In this study, the authors extended the Institute of Clinical and Economic Review’s (ICER) research of targeted immune modulators for the treatment of ulcerative colitis to identify optimal treatment sequencing. Using a net health benefit (NHB) at a cost threshold of $150,000 per quality-adjusted life-year (QALY) gained, the authors ranked optimal treatment sequences.
To access the full publication, visit https://www.jmcp.org/doi/full/10.18553/jmcp.2021.27.8.1046